✦ LIBER ✦
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
✍ Scribed by Eskens, F A L M; Mom, C H; Planting, A S T; Gietema, J A; Amelsberg, A; Huisman, H; van Doorn, L; Burger, H; Stopfer, P; Verweij, J
- Book ID
- 109999348
- Publisher
- Nature Publishing Group
- Year
- 2007
- Tongue
- English
- Weight
- 173 KB
- Volume
- 98
- Category
- Article
- ISSN
- 0007-0920
No coin nor oath required. For personal study only.